YHB Investment Advisors Inc. boosted its position in Bristol-Myers Squibb Co. (NYSE:BMY) by 8.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,008 shares of the biopharmaceutical company’s stock after buying an additional 4,805 shares during the period. YHB Investment Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $4,414,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of the company. Jolley Asset Management LLC raised its stake in shares of Bristol-Myers Squibb by 4.0% in the second quarter. Jolley Asset Management LLC now owns 2,092 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 80 shares in the last quarter. Univest Corp of Pennsylvania purchased a new stake in shares of Bristol-Myers Squibb during the second quarter worth $202,000. Smith & Howard Wealth Management LLC purchased a new stake in shares of Bristol-Myers Squibb during the first quarter worth $204,000. Windsor Financial Group LLC purchased a new stake in shares of Bristol-Myers Squibb during the second quarter worth $205,000. Finally, Balentine LLC raised its stake in shares of Bristol-Myers Squibb by 45.2% in the first quarter. Balentine LLC now owns 3,356 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 1,045 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.
Shares of Bristol-Myers Squibb Co. (NYSE:BMY) traded up 0.09% during mid-day trading on Friday, hitting $53.92. The company had a trading volume of 13,326,712 shares. The firm has a 50-day moving average price of $57.04 and a 200-day moving average price of $67.06. The firm has a market capitalization of $90.09 billion, a PE ratio of 31.53 and a beta of 0.61. Bristol-Myers Squibb Co. has a 52 week low of $53.76 and a 52 week high of $77.12.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The business had revenue of $4.90 billion for the quarter, compared to analysts’ expectations of $4.60 billion. Bristol-Myers Squibb had a return on equity of 24.92% and a net margin of 16.63%. The business’s revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.53 EPS. Equities analysts forecast that Bristol-Myers Squibb Co. will post $2.62 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 7th will be given a dividend of $0.38 per share. The ex-dividend date of this dividend is Wednesday, October 5th. This represents a $1.52 annualized dividend and a yield of 2.82%. Bristol-Myers Squibb’s payout ratio is 87.36%.
BMY has been the topic of several recent research reports. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a report on Wednesday, July 6th. Citigroup Inc. cut their target price on Bristol-Myers Squibb from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, August 3rd. Leerink Swann reaffirmed a “buy” rating and set a $85.00 target price on shares of Bristol-Myers Squibb in a report on Friday, July 29th. Vetr raised Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $78.73 target price on the stock in a report on Monday, July 25th. Finally, Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $85.00 target price on the stock in a report on Wednesday, July 13th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $69.91.
In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 23,200 shares of Bristol-Myers Squibb stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $59.17, for a total transaction of $1,372,744.00. Following the sale, the director now directly owns 364,999 shares of the company’s stock, valued at approximately $21,596,990.83. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.24% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.